Skip to main content
SpringerLink
Log in

Efficacy and Tolerability of 5- vs 10-Day Cefixime Therapy in Acute Exacerbations of Chronic Bronchitis

  • Clinical Use
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Summary

The efficacy and tolerability of oral cefixime 400mg once daily for 5 days was compared with standard 10-day therapy in a multicentre, double-blind, randomised, controlled clinical trial of 222 patients with acute exacerbations of chronic bronchitis. Clinical and bacteriological efficacy were assessed after 6, 11 and 30 days. A total of 167 patients were evaluable for efficacy on a per-protocol basis. Clinical efficacy (cure or improvement based on the quality and quantity of expectorated sputum and symptoms of dyspnoea) at day 11 was statistically equivalent (p < 0.01) between the treatment groups, with a successful clinical response achieved in 91% (5-day) and 89% (10-day) of patients. Bacteriological efficacy was also similar with 5- and 10-day treatment. During treatment, more patients reported an adverse event possibly or probably related to the study medication in the 10-day than in the 5-day treatment group (19 vs 14%). However, this difference was not statistically significant. Oral cefixime 400mg once daily is an effective and well tolerated treatment for acute exacerbations of chronic bronchitis. Short-term (5-day) therapy offers clinical efficacy similar to that of standard (10-day) therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Verghese A, Roberson D, Kalbfleisch JH, et al. Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis. Antimicrob Agents Chemother 1990; 34: 1041–4

    Article  PubMed  CAS  Google Scholar 

  2. Davies BI. Critical review of microbiological data and methods in diagnosis of lower respiratory tract infections. Monaldi Arch Chest Dis 1994; 49: 52–6

    PubMed  CAS  Google Scholar 

  3. Markham A, Brogden RN. Cefixime: a review of its therapeutic efficacy in lower respiratory tract infections. Drugs 1995; 49: 1007–22

    Article  PubMed  CAS  Google Scholar 

  4. Kiani R, Johnson D, Nelson B. Comparative, multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections. Am J Med 1988; 85: 6–13

    Article  PubMed  CAS  Google Scholar 

  5. Dorow P. Safety and efficacy of cefixime versus cefaclor in respiratory tract infections. J Chemother 1989; 1: 257–60

    PubMed  CAS  Google Scholar 

  6. Modai J. Efficacy and tolerability of cefixime in lower respiratory tract infections in adults: French multicentric study. Presse Med 1989; 18: 1605–7

    PubMed  CAS  Google Scholar 

  7. Neu HC, Chick TW. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest 1993; 194: 1393–9

    Article  Google Scholar 

  8. Cazzola M, Vinciguerra A, Beghi GF, et al. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. J Chemother 1995; 7: 432–41

    PubMed  CAS  Google Scholar 

  9. Quintiliani R. Cefixime in the treatment of patients with lower respiratory tract infections: results of US clinical trials. Clin Ther 1996; 18: 373–90

    Article  PubMed  CAS  Google Scholar 

  10. Cogo R, Monzani GP, Caiazzo G. Safety and efficacy of cefixime vs ceftriaxone in the treatment of infectious exacerbations of chronic bronchitis. J Drug Dev 1993; 6Suppl. 1: 55–6

    Google Scholar 

  11. Stratton CW. Efficacy and safety of cefixime for the empiric therapy of acute bronchitis and AECB. Infect Med 1993; 10Suppl. B: 11–15

    Google Scholar 

  12. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204

    PubMed  CAS  Google Scholar 

  13. Dunnett CW, Gent M. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2×2 tables. Biometrics 1977; 33: 593–602

    Article  PubMed  CAS  Google Scholar 

  14. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley, 1981

    Google Scholar 

  15. Boudignat O, Zylbertrest R, Roche G. Etude comparative de deux schemas dadministration du cefixime dans le traitement des infections otorhinolaryngees ou bronchiques. Presse Med 1989; 18: 1622–5

    PubMed  CAS  Google Scholar 

  16. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agents Dis 1994; 3: 266–73

    PubMed  CAS  Google Scholar 

  17. Hendrickse WA, Kusmiesz H, Shelton S, et al. Five vs ten days of therapy for acute otitis media. Pediatr Infect Dis 1988; 7: 14–23

    Article  CAS  Google Scholar 

  18. Portier H, Chavanet P, Waldner-Combernoux A, et al. Five versus ten days' treatment of streptococcal pharyngotonsillitis: a randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin. Scand J Infect Dis 1994; 26: 59–66

    Article  PubMed  CAS  Google Scholar 

  19. Henry D, Ruoff GE, Rhudy J, et al. Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis. Antimicrob Agents Chemother 1995; 39: 2528–34

    Article  PubMed  CAS  Google Scholar 

  20. Schito GC, Mannelli S, Pesce A. Trends in the activity of macrolide and beta-lactam antibiotics and resistance development. Alexander Project Group. J Chemother 1997; 9Suppl. 3: 18–28

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2nd Medical Department, District Hospital, Paulmanns-höherstrasse 14, D-58515, Lüdenscheid, Germany

    J. Lorenz (Head) & T. Keienburg

  2. Merck KGaA, Darmstadt, Germany

    P. Steinfeld & K. Troester

  3. Drs Kapp & Breuer Laboratory, Mainz, Germany

    L. Drath

Authors
  1. J. Lorenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Steinfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Drath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Keienburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Troester
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lorenz, J., Steinfeld, P., Drath, L. et al. Efficacy and Tolerability of 5- vs 10-Day Cefixime Therapy in Acute Exacerbations of Chronic Bronchitis. Clin. Drug Investig. 15, 13–20 (1998). https://doi.org/10.2165/00044011-199815010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-199815010-00002

Keywords

Search

Navigation